Northwest Biotherapeutics, Inc.
NWBO
$0.26
-$0.0096-3.56%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.04% | -48.09% | -12.07% | 153.73% | -67.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.04% | -48.09% | -12.07% | 153.73% | -67.73% |
| Cost of Revenue | 5.15% | 41.17% | 12.90% | 33.46% | 15.76% |
| Gross Profit | -4.15% | -46.84% | -14.39% | -29.44% | -28.04% |
| SG&A Expenses | 15.45% | 0.91% | -0.03% | 27.99% | 15.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.34% | 20.16% | 6.51% | 30.45% | 15.78% |
| Operating Income | -9.95% | -22.17% | -7.06% | -28.63% | -21.44% |
| Income Before Tax | -5.63% | -101.92% | 17.63% | -23.68% | -71.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.63% | -101.92% | 17.63% | -23.68% | -71.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.63% | -101.92% | 17.63% | -23.68% | -71.91% |
| EBIT | -9.95% | -22.17% | -7.06% | -28.63% | -21.44% |
| EBITDA | -10.19% | -22.72% | -7.06% | -28.75% | -21.28% |
| EPS Basic | 9.43% | -75.81% | 26.89% | -11.85% | -54.37% |
| Normalized Basic EPS | 23.40% | -51.22% | 16.13% | -8.86% | -74.07% |
| EPS Diluted | 9.43% | -75.81% | 5.66% | -48.15% | -54.37% |
| Normalized Diluted EPS | 23.40% | -51.22% | 16.13% | -8.86% | -74.07% |
| Average Basic Shares Outstanding | 14.42% | 12.87% | 10.95% | 9.55% | 10.54% |
| Average Diluted Shares Outstanding | 14.42% | 12.87% | 10.95% | 9.55% | 10.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |